The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …

Myeloid neoplasms with erythroid or megakaryocytic differentiation include pure erythroid
leukemia, myelodysplastic syndrome with erythroid features, and acute megakaryoblastic …

To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute
myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene …

Deregulation of the BCL2 gene family plays an important role in the pathogenesis of acute
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …

The BCL2 inhibitor venetoclax has recently emerged as an important component of acute
myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously …

The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML),
including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires …

Background BCL2 protein inhibitor venetoclax (ABT-199) has been authorized by Food and
Drug Administration for relapsed/refractory chronic lymphoid leukemia with 17p deletion …

Suppression of apoptosis by expression of antiapoptotic BCL2 family members is a hallmark
of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein …

Introduction: Overexpression of the antiapoptotic protein BCL-2 has been implicated in the
maintenance and survival of acute myelogenous leukemia (AML) cells and associated with …

Targeted therapies are frequently combined with standard cytotoxic drugs to enhance
clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive …